The Montreal Heart Institute (MHI) announced today that the COLCORONA clinical trial will continue to recruit non-hospitalized adult patients with COVID-19 as recommended by the control committee of independent data (DMC), following a second internal analysis.

"With the sharp increase in COVID-19 cases around the world, it is increasingly important that we continue to investigate treatments that not only help hospitalized patients with severe illness, but also those with milder symptoms and are in their homes ", highlighted Dr Jean-Claude Tardif , director of the Research Center at MHI, professor of Medicine at the University of Montreal , and COLCORONA chief researcher. "We want to complete patient enrollment in this large study in the next month and we hope that colchicine will reduce the risk of complications from COVID-19."

COLCORONA is a non-contact, home, randomized, double-blind, placebo-controlled study conducted in Canada, the United States, Europe, South America, and South Africa. It seeks to determine whether colchicine can reduce the risk of serious complications linked to COVID-19. This is one of the few current large-scale COVID-19 studies in which out-of-hospital patients can participate. 

COLCORONA is coordinated by the Montreal Health Innovations Coordination Center (MHICC) and is funded by the Government of Quebec , the Bill & Melinda Gates Foundation and the National Heart, Lung, and Blood Institute (NHLBI) of the United States National Institutes of Health (NIH). CGI, Dacima and Pharmascience are also COLCORONA collaborators.

The Montreal Cardiology Institute and its partners around the world would like to thank all the researchers and the thousands of participants for their continued participation in the COLCORONA study.